Neoanti­gen pi­o­neer Neon Ther­a­peu­tics casts off in search of $115M IPO to fu­el the race to a per­son­al­ized can­cer treat­ment

Can a be­spoke can­cer vac­cine ac­tu­al­ly suc­ceed in treat­ing in­di­vid­ual on­col­o­gy cas­es? 

Neon Ther­a­peu­tics launched three years ago, set­ting out on a mis­sion to prove that it could, and it now has enough ex­am­ples of a se­lect hand­ful of in­di­vid­ual re­spons­es to their neoanti­gen plat­form to gam­ble that in­vestors will come in to back a $115 mil­lion IPO as they look to tran­si­tion from their first ex­plorato­ry hu­man stud­ies in­to ad­vanced de­vel­op­ment work.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.